A Phase 2 interventional study of 124I-Evuzamitide in Amyloidosis and Transthyretin Amyloidosis, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Oregon Health and Science University · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States — 10 open to participants now, 12 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · United States.
Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, this one is the 11th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2023, is one of 2 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 30th registered.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →10 of the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Canada, China and 3 more countries
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States, Singapore, Spain
Ages 18–80
Eidos Therapeutics, a BridgeBio company · Sites in United States, Argentina, Australia and 21 more countries
Ages 18–75
AstraZeneca · Sites in United States, Canada, China and 3 more countries
Ages 18–130
Intellia Therapeutics · Sites in United States, Argentina, Australia and 23 more countries
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 40 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 10 · Phase 4 3
First in 2008; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Median enrollment 150 across the 23 interventional studies, 119 across the 14 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 37 have an industry lead sponsor. The 10 most frequent:
Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.
Oregon Health and Science University has 1 study filed under Amyloidosis, Hereditary, Transthyretin-Related — fewer than ten, so there is no comparison to draw.
2 of the studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05489523University of Texas Southwestern Medical CenterSafety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation | 2027-05-31 |
| NCT05489549University of Texas Southwestern Medical CenterSubclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 4) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET/MRI). In a subgroup of patients who are unable to undergo PET/MR, computed tomography will be used instead of MRI (i.e. PET/CT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
This study's planned enrollment of 150 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.
Compared within Amyloidosis, Hereditary, Transthyretin-Related, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Amyloidosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with ATTR-CM will undergo hybrid 124I-Evuzamitide PET/MRI imaging (or PET/CT) at baseline and in a subgroup, repeat imaging will be performed at an interval of 6-12 months.
Diagnostic Test: 124I-Evuzamitide
Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
Also known as: AT-01
I-124 evuzamitide diagnostic accuracy
To evaluate the efficacy of I-124 evuzamitide for diagnosing cardiac amyloidosis based on visual scan interpretation, compared to SoC site diagnosis. We will assess: * The sensitivity of PET/MRI with 124I-evuzamitide PET/MRI for the diagnosis of cardiac amyloidosis. * The specificity of PET/MRI with 124I-evuzamitide for the diagnosis of cardiac amyloidosis.
Time frame: At baseline scan
Quantitative measures
To evaluate the efficacy of I-124 evuzamitide for diagnosing cardiac amyloidosis based on quantitative scan interpretation, compared to SoC site diagnosis. We will assess the sensitivity and specificity of various quantitative measures, and evaluate inter- and intra-reader agreement.
Time frame: At baseline scan
Correlation between clinical cardiac biomarkers (i.e. stage of amyloidosis) and myocardial 124I-Evuzamitide uptake
Pearson Correlation Coefficient of stage of amyloidosis (Mayo Staging System) and SUV (124I-Evuzamitide)
Time frame: At baseline scan
Correlation between Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS) and myocardial 124I-Evuzamitide
Time frame: During baseline scan and follow up scan
Correlation between New York Heart Association (NYHA) class and 124I-Evuzamitide uptake
Time frame: During baseline scan and follow up scan
Correlation between liver and spleen ECV and their respective 124I-Evuzamitide uptake
Time frame: During baseline scan and follow up scan
Proportion of patients with ATTR-CM and MGUS or smoldering myeloma who are correctly classified as ATTR-CM based on 124I-Evuzamitide distribution and uptake
Time frame: During baseline scan
To evaluate the safety of a single intravenous administration of I-124 evuzamitide.
Incidence of related treatment-emergent (S)AEs from time of study drug administration to Day 7
Time frame: 7 days from baseline scan
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloidosis, Hereditary, Transthyretin-Related →
Oregon Health and Science University →